A recent publication in Advances in Radiation Oncology, led by Drs. Holly Grace and @AsalRahimiMD, describes two dermatologic conditions that may occur in patients following radiation therapy for breast cancer.
📖: bit.ly/4dgypFz
My first clinical trial! While was just short of our hypothesis that early salvage ISRT after CAR-T can double CR rate from d30 to d90 PET, interesting subset and translative analyses forthcoming for when this could be great salvage option post-CAR-T (e.g. single site of PR)…
During a session on clinical trials shaping the future of RT, Dr. @kakumar86 presented his work, “Phase II Trial of ‘Re-Priming’ Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after CAR-T Therapy.” #ASTRO25
I swear there were people there (just empty front row)!
Happy to have presented our pos phase II clinical trial results from PROMISE, which has revolutionized our ability to safely (with built in gating as safety mech) treat young children (3-7) without sedation! #ASTRO25
To close out a day of fantastic research, our Chief of Peds and Lymphoma Radiation Oncology Services, Dr. @kakumar86 presented his work during the Best of Physics session about the PROMISE clinical trial to reduce anesthesia use in pediatric patients undergoing RT. #ASTRO25
Do you have an interest in radiation oncology? Join our Virtual Meet and Greet next Wednesday! You'll have the opportunity talk with some of our faculty and medical residents about our medical residency program!
Zoom link🔗: bit.ly/46bdKQU
ALT A radiation oncology residency meet and greet graphic with details on the program and residency leadership with a photo of the resident group.
Join us for the second PULSAR Consortium Meeting at @ASTRO_org on Monday, September 29, at 6 p.m! This special meeting will feature in-depth discussions with leading experts on PULSAR in clinical practice. Register and learn more in the link below.
🔗: bit.ly/3Vng68X
ALT A blue flyer with details for a PULSAR Consortium Meeting on Monday, September 29 with listed information that includes speakers and location.
GI Pathology 101!
For each subsite, we go through path basics – histology, IHC & molecular markers, key features from resection specimen & more.
I ask @SuntreaHammer to explain path slides to me like I’m a 5-year-old 😀
Here's Part 1: CRC
Full video link & slides below🧵1/4:
As you take the next step in your careers, we celebrate the incredible journey of our graduating medical residents! Your commitment to excellence and patient care has been truly inspiring. Congratulations and best wishes for what lies ahead!
ALT A woman in a black flowery dress accepting a graduation certificate from program leadership.
ALT A woman in a black dress holding a baby, and accepting a graduation certificate from program leadership.
ALT A man in a blue suit accepting a graduation certificate from program leadership.
ALT A man in a gray suit accepting a graduation certificate from program leadership.
Congrats to our rising PGY-4 Brett Tortelli for being named one of the four 2025 ARRO-ASTRO Global Health Scholars 👏🏾
He has an awesome global health research year planned and this is just one of many awards/grants he’s received 💯 @UTSW_RadOnc
Announcing the 2025 ARRO-ASTRO Global Health Scholars! CONGRATULATIONS!
Dr. Bethel Adefres – Yale New Haven Hospital
Dr. Kara Banson – NYU Langone Health
Dr. Kelly Becht – Yale School of Medicine
Dr. Brett Tortelli – UT Southwestern Medical Center
Announcing the 2025 ARRO-ASTRO Global Health Scholars! CONGRATULATIONS!
Dr. Bethel Adefres – Yale New Haven Hospital
Dr. Kara Banson – NYU Langone Health
Dr. Kelly Becht – Yale School of Medicine
Dr. Brett Tortelli – UT Southwestern Medical Center
Congrats to our 5 graduating residents: Drs. Maureen Aliru, Ahmed Elamir, Meng-Lun Hsieh, Misha Miljanic, & Steven Montalvo.
Great doctors & even better people!
(Graduation was early this year, meaning we get another month w these awesome seniors).
Gonna miss them so much ❤️
Congrats to our two stellar @UTSW_RadOnc med students Katherine and Ethan on graduating today! Really proud of them for their successes and happy to see the tradition of matching @HarvardRadOnc continuing 🥹🥂🥳
Would argue that lymphomas are one of the most important diseases to consider adaptive RT as they are exquisitely radiosensitive, often in difficult to target locations, and many have long term survival so even small decreases in dose to OARs are likely meaningful. Excited… 1/2
Adaptive RT in lymphomas ➡️ better targeting w/ reduced margins, deceased dose to OARs, adaptation to shrinking tumors, shorter course treatments, & easier treatments of multi-targets/SIBs. Read @kakumar86@UTSW_RadOnc et al's article in the #RedJournal: tinyurl.com/kumarrj
To share our @UTSW_RadOnc experience of >70 lymphomas showing that oART was necessary to maintain PTV coverage with smaller margins and that tumors shrank on average 25% during RT. Safer and shorter course treatment options will hopefully expand the use of RT in lymphomas⚡️🤞🏾 2/2
Dosimetric advantages of online adaptive radiation therapy for head and neck squamous cell carcinoma: results from a prospective registry study by @davidshermd et al. Read about it in the #RedJournal: tinyurl.com/redsher1